Massachusetts General Hospital, Boston, MA, USA.
University of Milan, Milan, Italy.
Target Oncol. 2023 May;18(3):313-319. doi: 10.1007/s11523-023-00964-8. Epub 2023 May 3.
Breast cancer has been traditionally classified as either human epidermal growth factor receptor 2 (HER2)-positive or HER2-negative based on immunohistochemistry (IHC) scoring and/or gene amplification. HER2-positive breast cancer (defined as IHC 3+ or IHC 2+ and in situ hybridization [ISH]+) is routinely treated with HER2-targeted therapies, while HER2-negative breast cancer (defined as IHC 0, IHC 1+, or IHC 2+/ISH-) was not previously eligible for HER2-targeted therapy. Some tumors traditionally defined as HER2-negative express low levels of HER2 (i.e., HER2-low breast cancer, defined as IHC 1+ or IHC 2+/ISH-). Recently reported results from the DESTINY-Breast04 trial demonstrated that the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) improved survival in patients with previously treated advanced or metastatic HER2-low breast cancer, leading to the approval of T-DXd in the US and EU for patients with unresectable or metastatic HER2-low breast cancer after prior chemotherapy in the metastatic setting or disease recurrence within 6 months of adjuvant chemotherapy. As the first HER2-targeted therapy approved for the treatment of HER2-low breast cancer, this represents a change in the clinical landscape and presents new challenges, including identifying patients with HER2-low breast cancer. In this podcast, we discuss the strengths and limitations of current methodologies for classifying HER2 expression and future research that will help refine the identification of patients expected to benefit from HER2-targeted therapy, such as T‑DXd or other antibody-drug conjugates. Although current methodologies are not optimized to identify all patients with HER2-low breast cancer who may potentially benefit from HER2-targeted antibody-drug conjugates, they are likely to identify many. Ongoing studies-including the DESTINY-Breast06 trial evaluating T-DXd in patients with HER2-low breast cancer and those with tumors expressing very low levels of HER2 (IHC > 0 to < 1+)-will provide insights that may improve the identification of patient populations expected to benefit from HER2-targeted antibody-drug conjugates. Supplementary file1 (MP4 123466 KB).
乳腺癌传统上根据免疫组织化学(IHC)评分和/或基因扩增分为人表皮生长因子受体 2(HER2)阳性或 HER2 阴性。HER2 阳性乳腺癌(定义为 IHC 3+或 IHC 2+且原位杂交 [ISH]+)常规采用 HER2 靶向治疗,而 HER2 阴性乳腺癌(定义为 IHC 0、IHC 1+或 IHC 2+/ISH-)以前不符合 HER2 靶向治疗条件。一些传统上定义为 HER2 阴性的肿瘤表达低水平的 HER2(即 HER2 低表达乳腺癌,定义为 IHC 1+或 IHC 2+/ISH-)。最近来自 DESTINY-Breast04 试验的报告结果表明,HER2 靶向抗体药物偶联物 trastuzumab deruxtecan(T-DXd)可改善先前接受治疗的晚期或转移性 HER2 低表达乳腺癌患者的生存,这导致 T-DXd 在美欧获批用于先前在转移性环境中接受化疗或辅助化疗后 6 个月内疾病复发的不可切除或转移性 HER2 低表达乳腺癌患者。作为首个获批用于治疗 HER2 低表达乳腺癌的 HER2 靶向治疗药物,这代表着临床格局的改变,并带来了新的挑战,包括识别 HER2 低表达乳腺癌患者。在本播客中,我们讨论了目前用于分类 HER2 表达的方法的优缺点以及未来的研究,这些研究将有助于进一步确定有望从 HER2 靶向治疗中获益的患者,如 T-DXd 或其他抗体药物偶联物。尽管目前的方法不是为了确定所有可能从 HER2 靶向抗体药物偶联物中获益的 HER2 低表达乳腺癌患者,但它们很可能会识别出许多患者。正在进行的研究,包括评估 T-DXd 在 HER2 低表达乳腺癌患者和 HER2 表达水平非常低(IHC>0 至<1+)的肿瘤患者中的 DESTINY-Breast06 试验,将提供可能改善从 HER2 靶向抗体药物偶联物中获益的患者人群识别的见解。补充文件 1(MP4 123466KB)。